Discovery and biological characterization of a novel scaffold for potent inhibitors of peripheral serotonin synthesis

References

• 1. Matthes S, Bader M. Peripheral serotonin synthesis as a new drug target. Trends Pharmacol. Sci. 39(6), 560–572 (2018).
  Medline CASGoogle Scholar
• 2. Yadav VK, Balaji S, Suresh PS et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat. Med. 16(3), 308–312 (2010).
  Medline CASGoogle Scholar
• 3. Inose H, Zhou B, Yadav VK, Guo XE, Karsenty G, Ducy P. Efficacy of serotonin inhibition in mouse models of bone loss. J. Bone Miner. Res. 26(9), 2002–2011 (2011).
  Medline CASGoogle Scholar
• 4. Hallen A. Fibrosis in the carcinoid syndrome. Lancet 1(7336), 746–747 (1964).
  Medline CASGoogle Scholar
• 5. MacDonald RA, Robbins SL, Mallory GK. Dermal fibrosis following subcutaneous injections of serotonin creatinine sulphate. Proc. Soc. Exp. Biol. Med. 97(2), 334–337 (1958).
  Medline CASGoogle Scholar
• 6. Crane JD, Palanivel R, Mottillo EP et al. Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis. Nat. Med. 21(2), 166–172 (2015).
  Medline CASGoogle Scholar
• 7. Oh CM, Namkung J, Go Y et al. Regulation of systemic energy homeostasis by serotonin in adipose tissues. Nat. Commun. 6, 6794 (2015).
  Medline CASGoogle Scholar
• 8. Margolis KG, Stevanovic K, Li Z et al. Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. Gut 63(6), 928–937 (2014).
  Medline CASGoogle Scholar
• 9. Dempsie Y, Morecroft I, Welsh DJ et al. Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation 117(22), 2928–2937 (2008).
  Medline CASGoogle Scholar
• 10. Morecroft I, Dempsie Y, Bader M et al. Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 49(1), 232–236 (2007).
  Medline CASGoogle Scholar
• 11. Jacobsen KK, Kleppe R, Johansson S, Zayats T, Haavik J. Epistatic and gene wide effects in YWHA and aromatic amino hydroxylase genes across ADHD and other common neuropsychiatric disorders: association with YWHAE. Am. J. Med. Genet. B Neuropsychiatr. Genet. 168(6), 423–432 (2015).
  Medline CASGoogle Scholar
• 12. Zhang X, Gainetdinov RR, Beaulieu JM et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45(1), 11–16 (2005).
  Medline CASGoogle Scholar
• 13. Matthes S, Mosienko V, Bashammakh S, Alenina N, Bader M. Tryptophan hydroxylase as novel target for the treatment of depressive disorders. Pharmacology 85(2), 95–109 (2010).
  Medline CASGoogle Scholar
• 14. Patrick RP, Ames BN. Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism. FASEB J. 28(6), 2398–2413 (2014).
  Medline CASGoogle Scholar
• 15. Eissa N, Al-Houqani M, Sadeq A, Ojha SK, Sasse A, Sadek B. Current enlightenment about etiology and pharmacological treatment of autism spectrum disorder. Front. Neurosci. 12, 304 (2018).
  MedlineGoogle Scholar
• 16. Fitzpatrick PF, Ralph EC, Ellis HR, Willmon OJ, Daubner SC. Characterization of metal ligand mutants of tyrosine hydroxylase: insights into the plasticity of a 2-histidine-1-carboxylate triad. Biochemistry 42(7), 2081–2088 (2003).
  Medline CASGoogle Scholar
• 17. Abu-Omar MM, Loaiza A, Hontzeas N. Reaction mechanisms of mononuclear non-heme iron oxygenases. Chem. Rev. 105(6), 2227–2252 (2005).
  Medline CASGoogle Scholar
• 18. Walther DJ, Bader M. A unique central tryptophan hydroxylase isoform. Biochem. Pharmacol. 66(9), 1673–1680 (2003).
  Medline CASGoogle Scholar
• 19. Walther DJ, Peter JU, Bashammakh S et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299(5603), 76 (2003).
  Medline CASGoogle Scholar
• 20. McKinney J, Knappskog PM, Haavik J. Different properties of the central and peripheral forms of human tryptophan hydroxylase. J. Neurochem. 92(2), 311–320 (2005).
  Medline CASGoogle Scholar
• 21. Amireault P, Sibon D, Cote F. Life without peripheral serotonin: insights from tryptophan hydroxylase 1 knockout mice reveal the existence of paracrine/autocrine serotonergic networks. ACS Chem. Neurosci. 4(1), 64–71 (2013).
  Medline CASGoogle Scholar
• 22. Cote F, Thevenot E, Fligny C et al. Disruption of the nonneuronal TPH1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proc. Natl Acad. Sci. USA 100(23), 13525–13530 (2003).
  Medline CASGoogle Scholar
• 23. Malek ZS, Dardente H, Pevet P, Raison S. Tissue-specific expression of tryptophan hydroxylase mRNAs in the rat midbrain: anatomical evidence and daily profiles. Eur. J. Neurosci. 22(4), 895–901 (2005).
  MedlineGoogle Scholar
• 24. Gutknecht L, Waider J, Kraft S et al. Deficiency of brain 5-HT synthesis but serotonergic neuron formation in TPH2 knockout mice. J. Neural Transm. (Vienna) 115(8), 1127–1132 (2008).
  Medline CASGoogle Scholar
• 25. Waloen K, Kleppe R, Martinez A, Haavik J. Tyrosine and tryptophan hydroxylases as therapeutic targets in human disease. Expert Opin. Ther. Targets 21(2), 167–180 (2017).
  MedlineGoogle Scholar
• 26. Bader M. Inhibition of serotonin synthesis: a novel therapeutic paradigm. Pharmacol. Ther. 205, 107423 (2020).
  Medline CASGoogle Scholar
• 27. Engelman K, Lovenberg W, Sjoerdsma A. Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome. N. Engl. J. Med. 277(21), 1103–1108 (1967).
  Medline CASGoogle Scholar
• 28. Zimmer L, Luxen A, Giacomelli F, Pujol JF. Short- and long-term effects of p-ethynylphenylalanine on brain serotonin levels. Neurochem. Res. 27(4), 269–275 (2002).
  Medline CASGoogle Scholar
• 29. Cianchetta G, Stouch T, Yu W et al. Mechanism of inhibition of novel tryptophan hydroxylase inhibitors revealed by co-crystal structures and kinetic analysis. Curr. Chem. Genomics 4, 19–26 (2010).
  Medline CASGoogle Scholar
• 30. Goldberg DR, De Lombaert S, Aiello R et al. Optimization of spirocyclic proline tryptophan hydroxylase-1 inhibitors. Bioorg. Med. Chem. Lett. 27(3), 413–419 (2017).
  Medline CASGoogle Scholar
• 31. Markham A. Telotristat ethyl: first global approval. Drugs 77(7), 793–798 (2017).
  Medline CASGoogle Scholar
• 32. Masab M, Saif MW. Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea. Cancer Chemother. Pharmacol. 80(6), 1055–1062 (2017).
  Medline CASGoogle Scholar
• 33. Liu Q, Yang Q, Sun W et al. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J. Pharmacol. Exp. Ther. 325(1), 47–55 (2008).
  Medline CASGoogle Scholar
• 34. Shi H, Cui Y, Qin Y. Discovery and characterization of a novel tryptophan hydroxylase 1 inhibitor as a prodrug. Chem. Biol. Drug Des. 91(1), 202–212 (2018).
  MedlineGoogle Scholar
• 35. Petrassi M, Barber R, Be C et al. Identification of a novel allosteric inhibitory site on tryptophan hydroxylase 1 enabling unprecedented selectivity over all related hydroxylases. Front. Pharmacol. 8, 240 (2017).
  MedlineGoogle Scholar
• 36. Teigen K, McKinney JA, Haavik J, Martinez A. Selectivity and affinity determinants for ligand binding to the aromatic amino acid hydroxylases. Curr. Med. Chem. 14(4), 455–467 (2007).
  Medline CASGoogle Scholar
• 37. Lo MC, Aulabaugh A, Jin G et al. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal. Biochem. 332(1), 153–159 (2004).
  Medline CASGoogle Scholar
• 38. Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2(9), 2212–2221 (2007).
  Medline CASGoogle Scholar
• 39. Wang L, Erlandsen H, Haavik J, Knappskog PM, Stevens RC. Three-dimensional structure of human tryptophan hydroxylase and its implications for the biosynthesis of the neurotransmitters serotonin and melatonin. Biochemistry 41(42), 12569–12574 (2002).
  Medline CASGoogle Scholar
• 40. McKinney J, Knappskog PM, Pereira J et al. Expression and purification of human tryptophan hydroxylase from Escherichia coli and Pichia pastoris. Protein Expr. Purif. 33(2), 185–194 (2004).
  Medline CASGoogle Scholar
• 41. Winge I, McKinney JA, Knappskog PM, Haavik J. Characterization of wild-type and mutant forms of human tryptophan hydroxylase 2. J. Neurochem. 100(6), 1648–1657 (2007).
  Medline CASGoogle Scholar
• 42. Flydal MI, Chatfield CH, Zheng H et al. Phenylalanine hydroxylase from Legionella pneumophila is a thermostable enzyme with a major functional role in pyomelanin synthesis. PLoS ONE 7(9), e46209 (2012).
  Medline CASGoogle Scholar
• 43. Aubi O, Flydal MI, Zheng H et al. Discovery of a specific inhibitor of pyomelanin synthesis in Legionella pneumophila. J. Med. Chem. 58(21), 8402–8412 (2015).
  Medline CASGoogle Scholar
• 44. Haavik J, Flatmark T. Rapid and sensitive assay of tyrosine 3-monooxygenase activity by high-performance liquid chromatography using the native fluorescence of DOPA. J. Chromatogr. 198(4), 511–515 (1980).
  Medline CASGoogle Scholar
• 45. Szigetvari PD, Muruganandam G, Kallio JP et al. The quaternary structure of human tyrosine hydroxylase: effects of dystonia-associated missense variants on oligomeric state and enzyme activity. J. Neurochem. 148(2), 291–306 (2019).
  Medline CASGoogle Scholar
• 46. Friesner RA, Murphy RB, Repasky MP et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49(21), 6177–6196 (2006).
  Medline CASGoogle Scholar
• 47. Dai R, Geders TW, Liu F et al. Fragment-based exploration of binding site flexibility in Mycobacterium tuberculosis BioA. J. Med. Chem. 58(13), 5208–5217 (2015).
  Medline CASGoogle Scholar
• 48. Morreale FE, Bortoluzzi A, Chaugule VK, Arkinson C, Walden H, Ciulli A. Allosteric targeting of the Fanconi anemia ubiquitin-conjugating enzyme Ube2T by fragment screening. J. Med. Chem. 60(9), 4093–4098 (2017).
  Medline CASGoogle Scholar
• 49. Sayegh J, Cao J, Zou MR et al. Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J. Biol. Chem. 288(13), 9408–9417 (2013).
  Medline CASGoogle Scholar
• 50. Calvo AC, Scherer T, Pey AL et al. Effect of pharmacological chaperones on brain tyrosine hydroxylase and tryptophan hydroxylase 2. J. Neurochem. 114(3), 853–863 (2010).
  Medline CASGoogle Scholar
• 51. Thony B, Calvo AC, Scherer T et al. Tetrahydrobiopterin shows chaperone activity for tyrosine hydroxylase. J. Neurochem. 106(2), 672–681 (2008).
  Medline CASGoogle Scholar
• 52. Frantom PA, Seravalli J, Ragsdale SW, Fitzpatrick PF. Reduction and oxidation of the active site iron in tyrosine hydroxylase: kinetics and specificity. Biochemistry 45(7), 2372–2379 (2006).
  Medline CASGoogle Scholar
• 53. Renson J, Weissbach H, Udenfriend S. Hydroxylation of tryptophan by phenylalanine hydroxylase. J. Biol. Chem. 237, 2261–2264 (1962).
  Medline CASGoogle Scholar
• 54. Jin H, Cianchetta G, Devasagayaraj A et al. Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids as novel tryptophan hydroxylase inhibitors. Bioorg. Med. Chem. Lett. 19(17), 5229–5232 (2009).
  Medline CASGoogle Scholar
• 55. Shi ZC, Devasagayaraj A, Gu K et al. Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders. J. Med. Chem. 51(13), 3684–3687 (2008).
  Medline CASGoogle Scholar
• 56. Ouyang L, He G, Huang W, Song X, Wu F, Xiang M. Combined structure-based pharmacophore and 3D-QSAR studies on phenylalanine series compounds as TPH1 inhibitors. Int. J. Mol. Sci. 13(5), 5348–5363 (2012).
  Medline CASGoogle Scholar